JERUSALEM, Jan. 25,
2024 /PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on
development of inflammation and immunology (I&I) biological
products, congratulates the Company's co-lead scientific
research collaborator Professor Dr. Dirk
Görlich on being awarded the 2024 Louis-Jeantet Prize.
Established in 1986, the prestigious CHF
500,000 (US$ 576,000) prize is
awarded annually to European-based researchers in recognition of
groundbreaking work in the field of biomedicine.
Görlich serves as a director of the Max Planck Institute for
Multidisciplinary Sciences (MPI-NAT). In close collaboration with
Scinai, the teams led by Görlich and Prof. Dr. Matthias Dobbelstein of the University
Medical Center Göttingen (UMG), lead discovery of nanosized VHH
antibodies (NanoAbs), which form the basis of Scinai's innovative,
de-risked, pipeline targeting inflammation and immunology (I&I)
biological therapeutic diseases. A recently completed ex-vivo study
indicated the potential of Scinai's anti-IL-17 NanoAb to
effectively and conveniently treat mild to moderate plaque
psoriasis. These results followed earlier proof-of-concept in-vivo
studies indicating the potential of inhaled NanoAbs to treat and
prevent infectious viral respiratory disease. Those results were
reported in an article published in the prestigious scientific
journal Antiviral Research and co-authored by Görlich, Dobbelstein,
and Scinai's CSO Dr. Tamar
Ben-Yedidia, among others.
According to MPI-NAT, Görlich has received several other
scientific awards including the Heinz Maier-Leibnitz Prize, the
EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022, and
the Animal Welfare Research Prize of the German Federal Ministry of
Food and Agriculture.
Amir Reichman, Scinai's
CEO, commented, "On behalf of Scinai's team, I offer sincere
congratulations to Dirk on being awarded the 2024 Louis-Jeantet
Prize. The award provides significant evidence of the creativity,
professionalism, and elite scientific acumen of the scientist
leading the discovery of our pipeline of innovative NanoAb-based
therapeutic products."
According to MPI-NAT, Görlich was awarded the prize for
"discovering a new kind of biological matter that acts as a highly
selective barrier to control central transport pathways in the
cell," and "groundbreaking contributions to our understanding of
the processes by which macromolecules are transported into and out
of the cell nucleus."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked, pipeline of nanosized VHH antibodies
(NanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical GMP manufacturing, and
pre-clinical and clinical trial design and execution services to
early stage biotech companies. Company website:
www.scinai.com.
Company Contact
Joshua Phillipson
+972 8 930 2529
joshua.phillipson@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, the potential of
Scinai's anti-IL-17 NanoAb. These forward-looking
statements reflect management's current views with respect to
certain current and future events and are subject to various risks,
uncertainties and assumptions that could cause the results to
differ materially from those expected by the management of
Scinai Immunotherapeutics Ltd. Risks and
uncertainties include, but are not limited to, the risk of delay
in, or Scinai's inability to conduct, its research and development
activities, including the contemplated in-vivo and
toxicology studies and a clinical trial; the risk that
Scinai will not remain listed on Nasdaq; the risk that Scinai will
not be successful in growing its CDMO business or in-license
other NanoAbs; the risk that Scinai may not be able to
secure additional capital on attractive terms, if at all; the risk
that the therapeutic and commercial potential of NanoAbs will not
be met; the risk of a delay in the preclinical and clinical trials
data for NanoAbs, if any; the risk that our business strategy may
not be successful; the risk that the European Investment Bank (EIB)
may accelerate the financial facility under its finance contract
with Scinai; Scinai's ability to acquire rights to additional
product opportunities; Scinai's ability to enter into
collaborations on terms acceptable to Scinai or at all; timing of
receipt of regulatory approval of Scinai's manufacturing facility
in Jerusalem, if at all or when
required; the risk that the manufacturing facility will not be able
to be used for a wide variety of applications and other vaccine and
treatment technologies; and the risk that drug development involves
a lengthy and expensive process with uncertain outcomes. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission ("SEC") on April 17,
2023, and the Company's subsequent filings with the SEC.
Scinai undertakes no obligation to revise or update any
forward-looking statement for any reason.
View original
content:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-congratulates-its-co-lead-scientific-research-collaborator-dirk-gorlich-on-louis-jeantet-prize-302044842.html
SOURCE Scinai Immunotherapeutics Ltd.